[go: up one dir, main page]

CO6650414A2 - Enhanced complement 2 receiver target groups - Google Patents

Enhanced complement 2 receiver target groups

Info

Publication number
CO6650414A2
CO6650414A2 CO12226385A CO12226385A CO6650414A2 CO 6650414 A2 CO6650414 A2 CO 6650414A2 CO 12226385 A CO12226385 A CO 12226385A CO 12226385 A CO12226385 A CO 12226385A CO 6650414 A2 CO6650414 A2 CO 6650414A2
Authority
CO
Colombia
Prior art keywords
complement
selectively
target groups
enhanced complement
modulators
Prior art date
Application number
CO12226385A
Other languages
Spanish (es)
Inventor
James Kovacs
Jonathan P Hannan
V Michael Holers
Original Assignee
Univ Colorado Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Colorado Regents filed Critical Univ Colorado Regents
Publication of CO6650414A2 publication Critical patent/CO6650414A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)

Abstract

En la presente se proporcionan composiciones y métodos dirigidos a proteínas solubles que pueden entregar selectivamente moduladores de actividad de complemento. La entrega dirigida de estos moduladores se realiza mutando selectivamente aminoácidos particulares en una porción de proteína objetivo de la composición correspondiente a al menos los dos primeros dominios de SCR N-terminales de CR2. Dependiendo de la combinación particular de mutaciones introducidas a la porción focalizada, una actividad de modulador de complemento puede entregarse selectivamente a ligandos particulares de CR2 en sitios donde se desea activación o supresión de sistema de complemento.Compositions and methods directed to soluble proteins that can selectively deliver complement activity modulators are provided herein. The targeted delivery of these modulators is performed by selectively mutating particular amino acids in a portion of the target protein of the composition corresponding to at least the first two N-terminal SCR domains of CR2. Depending on the particular combination of mutations introduced to the focused portion, a complement modulator activity can be selectively delivered to particular CR2 ligands at sites where activation or suppression of complement system is desired.

CO12226385A 2010-05-14 2012-12-13 Enhanced complement 2 receiver target groups CO6650414A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34503510P 2010-05-14 2010-05-14

Publications (1)

Publication Number Publication Date
CO6650414A2 true CO6650414A2 (en) 2013-04-15

Family

ID=44914740

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12226385A CO6650414A2 (en) 2010-05-14 2012-12-13 Enhanced complement 2 receiver target groups

Country Status (18)

Country Link
US (1) US9650447B2 (en)
EP (1) EP2569332B1 (en)
JP (1) JP5986990B2 (en)
KR (1) KR20130080443A (en)
CN (1) CN103038252A (en)
AU (1) AU2011252864B2 (en)
BR (1) BR112012029067A2 (en)
CA (1) CA2799192A1 (en)
CO (1) CO6650414A2 (en)
EA (1) EA201291241A1 (en)
ES (1) ES2717912T3 (en)
IL (1) IL222881A0 (en)
MX (1) MX2012013233A (en)
NZ (1) NZ603560A (en)
SG (1) SG185483A1 (en)
TR (1) TR201904224T4 (en)
WO (1) WO2011143637A1 (en)
ZA (1) ZA201208579B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2432112T3 (en) 2004-02-10 2013-11-29 The Regents Of The University Of Colorado, A Body Corporate Inhibition of factor B, of the alternative complement pathway and related methods
EP1885398B1 (en) 2005-05-26 2015-07-08 The Regents of the University of Colorado, a body corporate Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
JP5250548B2 (en) 2006-06-21 2013-07-31 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント Targeting complement factor H for the treatment of disease
BRPI0808227A2 (en) 2007-03-14 2014-07-08 Taligen Therapeutics Inc HUMANIZED ANTI-FACTOR B ANTIBODY
RS20120461A1 (en) 2009-07-02 2013-06-28 Musc Foundation For Research Development Methods of stimulating liver regeneration
CA2795311A1 (en) 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
KR20130080443A (en) 2010-05-14 2013-07-12 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 Improved complement receptor 2(cr2) targeting groups
CN103249432A (en) 2010-06-22 2013-08-14 科罗拉多大学董事会,法人团体 Antibodies to the c3d fragment of complement component 3
SG10201506959SA (en) 2010-09-03 2015-10-29 Stemcentrx Inc Novel modulators and methods of use
WO2012095519A1 (en) * 2011-01-13 2012-07-19 Leibniz-Institut Für Naturstoff-Forschung Und Infektionsbiologie Potent inhibitors of complement activation
US20180021376A1 (en) * 2011-03-04 2018-01-25 Rare Antibody Antigen Supply, Inc. Naming of KH1 through KH55 good healthy cells synthesizes the KH1 through KH55 proteins
EP2855529A4 (en) 2012-05-24 2015-12-09 Alexion Pharma Inc Humaneered anti-factor b antibody
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
KR102448976B1 (en) 2013-08-07 2022-09-29 알렉시온 파마슈티칼스, 인코포레이티드 Atypical hemolytic uremic syndrome (ahus) biomarker proteins
AU2015266997A1 (en) * 2014-05-28 2016-12-08 Rare Antibody Antigen Supply, Inc. Purified compositions of IVIG and KH proteins for modulating lymphocytes and treating hepatitis B virus
US20190016766A1 (en) * 2015-10-07 2019-01-17 Daniel E. Benjamin Use of improved modulators of complement function as cancer therapeutics
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
SG11202010596PA (en) * 2018-05-16 2020-11-27 Csl Ltd Soluble complement receptor type 1 variants and uses thereof
JP7653909B2 (en) 2018-09-06 2025-03-31 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Humanized anti-C5 antibodies and their uses
CN109929026B (en) * 2019-03-15 2020-10-13 北京康普美特创新医药科技有限责任公司 Human target complement inhibitor protein mCR2-DAF and application thereof
SG11202111419QA (en) * 2019-04-24 2021-11-29 Univ Pennsylvania Bi-functional humanized anti-c5 antibodies and factor h fusion proteins and uses thereof
CN110128547B (en) * 2019-05-07 2022-07-22 北京康普美特创新医药科技有限责任公司 Human target complement inhibitor protein mCR2-fH and application thereof
GB201912437D0 (en) * 2019-08-30 2019-10-16 Glaxosmithkline Ip Dev Ltd CR2 Binding Proteins and their use in Medical Therapy
CN111763243B (en) * 2020-05-22 2021-01-29 浙江海洋大学 Gorgon fish immune active peptide and preparation method and application thereof
JP2024520497A (en) 2021-05-28 2024-05-24 アレクシオン ファーマシューティカルズ， インコーポレイテッド Methods for detecting CM-TMA biomarkers
WO2025015317A2 (en) * 2023-07-13 2025-01-16 Kriya Therapeutics, Inc. Complement pathway inhibitor fusions and methods of using the same

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212071A (en) 1988-04-01 1993-05-18 The Johns Hopkins University Nucleic acids encoding a human C3b/C4b receptor (CR1)
US5981481A (en) 1974-12-06 1999-11-09 The Johns Hopkins University Human C3b/C4b receptor (CR1)
JPH0742235B2 (en) 1985-11-08 1995-05-10 三共株式会社 Prophylactic / therapeutic agent for autoimmune diseases
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5256642A (en) 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
DE3830271A1 (en) 1988-09-06 1990-03-15 Goetze Otto MEDIUM WITH IMMUNE SUPPRESSIVE EFFECT
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
FR2648133B1 (en) 1989-06-08 1992-02-21 Sanofi Sa N-SUBSTITUTED LAURAMIDES, THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM
US5310729A (en) 1990-04-20 1994-05-10 California Institute Of Biological Research Interferon-related polypeptides as CR2 ligands and their use for modulating immune cell functions
US5331090A (en) 1989-09-08 1994-07-19 California Institute Of Biological Research CR2 ligand compositions and methods for modulating immune cell functions
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
EP0512733A2 (en) 1991-05-03 1992-11-11 Washington University Modified complement system regulator
DE4222534A1 (en) 1992-07-09 1994-01-13 Behringwerke Ag Use of complement inhibitors for the manufacture of a medicament for the prophylaxis and therapy of inflammatory bowel and skin diseases and purpura
US5679546A (en) 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5679345A (en) 1994-06-02 1997-10-21 The Johns Hopkins University Method for preventing complement-dependent rejection of organ or tissue transplants
WO1996012741A1 (en) 1994-10-25 1996-05-02 Glaxo Group Limited Binding agents to cd23
US5922320A (en) 1996-06-14 1999-07-13 Georgetown University Recombinant proCVF
AU3487697A (en) 1996-06-14 1998-01-07 Johns Hopkins University School Of Medicine, The Use of chimeric vaccinia virus complement control proteins to inhibit complement
AU733890B2 (en) 1996-08-21 2001-05-31 Sugen, Inc. Crystal structures of a protein tyrosine kinase
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
GB9624731D0 (en) 1996-11-28 1997-01-15 Univ Leicester Complement inhibitor
AU8296098A (en) 1997-07-08 1999-02-08 Board Of Regents, The University Of Texas System Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
WO1999037149A1 (en) 1998-01-27 1999-07-29 Brigham & Women's Hospital Methods of treating cytotoxic damage
NZ506920A (en) 1998-02-20 2003-12-19 Tanox Inc Inhibitors of complement activation
US7112327B2 (en) 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
WO1999044625A1 (en) 1998-03-03 1999-09-10 John Hopkins University Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation
CA2331258C (en) 1998-06-12 2011-09-20 Henry M. Jackson Foundation For The Advancement Of Military Medicine Enhancement of b cell activation and immunoglobulin secretion by co-stimulation of receptors for antigen and ebv gp350/220
US6572856B1 (en) 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
EP1001021B1 (en) 1998-09-25 2003-08-27 Wolfgang Prodinger Monoclonal antibody to human CD21, and its uses
US6224866B1 (en) 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
ATE352559T1 (en) 1998-12-08 2007-02-15 Biovation Ltd METHOD FOR REDUCING THE IMMUNOGENICITY OF PROTEINS
CA2359816C (en) 1999-01-06 2010-08-03 Genenews Inc. Method for the detection of gene transcripts in blood and uses thereof
CN100358577C (en) 1999-05-07 2008-01-02 杰南技术公司 Use of antibody in preparation of reagents for treating autoimmune diseases in mammals
US7576182B1 (en) 1999-08-31 2009-08-18 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
GB0008582D0 (en) 2000-04-08 2000-05-31 Adprotech Plc DNA immunization vectors
DE60136272D1 (en) 2000-04-29 2008-12-04 Univ Iowa Res Found DIAGNOSTICS AND THERAPEUTICS FOR MACULAR DEGENERATION DISEASES
US7439330B2 (en) 2000-05-08 2008-10-21 President And Fellows Of Harvard College Anti-glycated CD59 antibodies and uses thereof
MXPA03002262A (en) 2000-09-18 2003-10-15 Idec Pharma Corp Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination.
AU2002255478A1 (en) 2001-01-10 2002-09-12 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
JP2004528025A (en) 2001-02-21 2004-09-16 サーロメッド・インコーポレーテッド Modified annexin proteins and methods for preventing thrombosis
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US6820011B2 (en) * 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
WO2002092011A2 (en) 2001-05-17 2002-11-21 La Jolla Pharmaceutical Company Methods of treating antibody-mediated pathologies using agents which inhibit cd21
US7378094B2 (en) 2001-08-29 2008-05-27 University Of Virginia Patent Foundation Therapeutic uses of complement receptor 2
EP1336618A1 (en) 2002-02-15 2003-08-20 HANS-KNÖLL-INSTITUT FÜR NATURSTOFF-FORSCHUNG e.V. Porcine complement regulator factor H and its use
US20030180292A1 (en) 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
CN100594037C (en) 2002-11-15 2010-03-17 Musc研究发展基金会 Complement modulator directed through complement receptor 2
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
US20070134260A1 (en) 2003-03-28 2007-06-14 Georg Feger Use of clusterin for the treatment and/or prevention of peripheral neurological diseases
US20070123466A1 (en) 2003-05-13 2007-05-31 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method of treating recurrent miscarriages
JP4029772B2 (en) 2003-05-16 2008-01-09 株式会社日立製作所 Magnetic head and magnetic recording / reproducing apparatus using the same
EP1488798A1 (en) 2003-06-18 2004-12-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) HIP/PAP polypeptide composition for use in liver regeneration and for the prevention of liver failure
US20050079184A1 (en) 2003-08-08 2005-04-14 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
US20050112130A1 (en) 2003-11-05 2005-05-26 Bhat Neelima M. Enhanced B cell cytotoxicity of CDIM binding antibody
US8454963B2 (en) 2003-11-13 2013-06-04 Musc Foundation For Research Development Tissue targeted complement modulators
CA2554729A1 (en) 2004-01-27 2005-08-11 University Of Southern California Polymer-bound antibody cancer therapeutic agent
CA2561531C (en) 2004-02-10 2017-05-02 The Regents Of The University Of Colorado Inhibition of factor b, the alternative complement pathway and methods related thereto
ES2432112T3 (en) 2004-02-10 2013-11-29 The Regents Of The University Of Colorado, A Body Corporate Inhibition of factor B, of the alternative complement pathway and related methods
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
NZ553809A (en) 2004-09-03 2010-03-26 Creabilis Therapeutics Spa Use of polypeptides obtained through systematic mutations of single amino acids of human and non-human box-A of HMGB1 to prevent and/or antagonize pathologies induced by HMGB1
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
CN102618644A (en) 2004-11-18 2012-08-01 耶鲁大学 Methods and compositions for treating ocular disorders
CA2593846A1 (en) 2005-01-14 2006-08-10 The Regents Of The University Of California Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
MX2007009565A (en) 2005-02-14 2008-03-10 Univ Iowa Res Found Methods and reagents for treatment and diagnosis of age-related macular degeneration.
EP1885398B1 (en) 2005-05-26 2015-07-08 The Regents of the University of Colorado, a body corporate Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
CA2616863A1 (en) 2005-07-29 2007-02-01 Australian Stem Cell Centre Limited Compositions and methods for growth of pluripotent cells
US20090155381A1 (en) 2005-09-08 2009-06-18 Regina Goralczyc Method of treatment or prevention of age-related macular degeneration
EP1933870A2 (en) 2005-09-19 2008-06-25 Palingen Inc. Treatment of b cell diseases using anti-germline antibody binding agents
AU2006311803C1 (en) 2005-11-04 2015-05-14 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
WO2007112403A2 (en) 2006-03-27 2007-10-04 The Regents Of The University Of Colorado Prevention and treatment of ischemia-reperfusion injury
WO2007124299A2 (en) 2006-04-21 2007-11-01 Novartis Ag Antagonist anti-cd40 antibody pharmaceutical compositions
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
JP5250548B2 (en) 2006-06-21 2013-07-31 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント Targeting complement factor H for the treatment of disease
US7705475B2 (en) 2006-08-03 2010-04-27 Stats Chippac Ltd. Integrated circuit package system
RU2474589C9 (en) 2006-11-02 2019-08-15 Дженентек, Инк. Humanised anti-factor d antibodies and use thereof
BRPI0808227A2 (en) 2007-03-14 2014-07-08 Taligen Therapeutics Inc HUMANIZED ANTI-FACTOR B ANTIBODY
KR20170023212A (en) 2007-06-07 2017-03-02 제넨테크, 인크. C3b antibodies and methods for the prevention and treatment of complement-associated disorders
CN101970002B (en) 2007-08-27 2016-05-18 诺福麦德治疗学股份有限公司 By the method for inhibiting complement activation with factor bb specific antibodies
CL2008003241A1 (en) 2007-11-02 2009-07-31 Novartis Ag Binding molecule comprising an antigen-binding portion that binds to a c3b neoepitope; pharmaceutical composition comprising it; and its use to treat eye disorders
EP2262831B1 (en) 2008-03-03 2015-01-21 NovelMed Therapeutics, Inc. Anti-properdin antibodies
EP2815766B1 (en) 2008-08-05 2017-07-05 Novartis AG Compositions and methods for antibodies targeting complement protein C5
US20120108492A1 (en) * 2008-09-19 2012-05-03 The Regents Of The University Of Colorado Ligand-specific non-antibody compounds that inhibit cr2 activation and methods of use thereof
BRPI0921845A2 (en) 2008-11-12 2019-09-17 Medimmune Llc stable sterile aqueous formulation, pharmaceutical unit dosage form, pre-filled syringe, and methods for treating a disease or disorder, treating or preventing rejection, depleting unique expressing t cells in a human patient, and disrupting central germinal architecture in a secondary lymphoid organ of a primate
WO2010091183A2 (en) 2009-02-04 2010-08-12 The Regents Of The University Of Colorado, A Body Corporate Non-invasive detection of complement-mediated inflammation using cr2-targeted nanoparticles
US20100291106A1 (en) 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
US9291622B2 (en) 2009-05-21 2016-03-22 Apellis Pharmaceuticals, Inc. Complement assays and uses thereof
RS20120461A1 (en) 2009-07-02 2013-06-28 Musc Foundation For Research Development Methods of stimulating liver regeneration
CA2795311A1 (en) 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
KR20130080443A (en) 2010-05-14 2013-07-12 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 Improved complement receptor 2(cr2) targeting groups
CN103249432A (en) 2010-06-22 2013-08-14 科罗拉多大学董事会,法人团体 Antibodies to the c3d fragment of complement component 3
CN103248395A (en) 2012-02-09 2013-08-14 中兴通讯股份有限公司 Narrow-band interference suppression method and device
EP2855529A4 (en) 2012-05-24 2015-12-09 Alexion Pharma Inc Humaneered anti-factor b antibody

Also Published As

Publication number Publication date
BR112012029067A2 (en) 2019-09-24
AU2011252864A1 (en) 2012-11-29
KR20130080443A (en) 2013-07-12
US20130190477A1 (en) 2013-07-25
EP2569332B1 (en) 2019-01-09
AU2011252864B2 (en) 2015-11-05
EP2569332A1 (en) 2013-03-20
EA201291241A1 (en) 2013-05-30
JP2013529202A (en) 2013-07-18
JP5986990B2 (en) 2016-09-06
EP2569332A4 (en) 2013-10-23
SG185483A1 (en) 2012-12-28
ZA201208579B (en) 2015-05-27
MX2012013233A (en) 2013-05-20
CA2799192A1 (en) 2011-11-17
ES2717912T3 (en) 2019-06-26
CN103038252A (en) 2013-04-10
NZ603560A (en) 2014-09-26
TR201904224T4 (en) 2019-05-21
IL222881A0 (en) 2012-12-31
WO2011143637A1 (en) 2011-11-17
US9650447B2 (en) 2017-05-16

Similar Documents

Publication Publication Date Title
CO6650414A2 (en) Enhanced complement 2 receiver target groups
PH12017500866A1 (en) Targeted xten conjugate compositions and methods of making same
DE602006014821D1 (en) EX-VIVO GENERATION PROCEDURE
CY1120485T1 (en) METHODS FOR CONNECTION OF Peptide-Targets With Recombinant Lysosomal Enzymes For Improved Therapeutic Therapies For Diarrheal Disorders
MX2018010824A (en) Inducible binding proteins and methods of use.
BR112015004696A2 (en) chimeric polypeptides having targeted binding specificity
BR112012026801B8 (en) targeted pyrrolobenzodiazepine conjugates, pharmaceutical composition, use thereof for treatment of a proliferative or autoimmune disease and drug binding
HRP20220214T1 (en) Immunomodulatory agents
BR112016004095A2 (en) administration of quinurenine depletion enzymes for tumor therapy
MX360208B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX363136B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
IN2014KN01716A (en)
WO2017044894A3 (en) Cartilage-homing peptides
MX336391B (en) Methods and compositions using fgf23 fusion polypeptides.
MX2018011836A (en) Anti-cd70 antibody drug conjugates.
NZ731185A (en) Bicyclic peptide ligands specific for mt1-mmp
PH12016500372A1 (en) Pharmaceutical composition containing pyrimidine compound as active ingredient
EA201291138A1 (en) METHODS, COMPOSITIONS AND KITS FOR THE TREATMENT OF VIOLATIONS CONNECTED WITH MATRIX MINERALIZATION
WO2014062697A3 (en) Drug delivery conjugates containing unnatural amino acids and methods for using
WO2016022994A3 (en) High affinity pd-1 agents and methods of use
WO2015031726A3 (en) Engineered primate l-methioninase for therapeutic purposes
BR112013003361B8 (en) Antibody, composition, antibody conjugate, pharmaceutical formulation and antibody usage
BR112013003825A2 (en) related conjugates, particles, compositions and methods
MX367024B (en) Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof.
WO2011005540A8 (en) Methods and compositions using peptides and proteins with c-terminal elements